Figure 3.

Activation of collicular CB1/2 receptors is sufficient, but not necessary to account for the anticonvulsant effect of systemic WIN 55,212-2 (WIN) in GEPRs. (A) Schematic of the testing scheme; animals were tested with a baseline test session before each of the four test conditions. Animals received either vehicle (VEH) or SR 141716 (SR) infusion into the DLSC followed by VEH or WIN (2 mg/kg, i.p.). (B) AGS score as a function of drug treatments. WIN administration significantly reduced AGS severity as compared to the pre-administration baseline. SR administration was without effect on audiogenic seizures (AGSs) but failed to reverse the anticonvulsant action of WIN. Bars show median and interquartile range, symbols show individual subjects. *p < 0.05, according to Friedman test followed by Dunn’s post hoc test.